Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diffuse large B-cell lymphoma: current standard treatment and future perspectives.

[Rinsho ketsueki] The Japanese journal of clinical hematology - 1 Jan 2016

Ohmachi Ken

Abstract excerpt

The current standard treatment for diffuse large B-cell lymphoma (DLBCL) is R-CHOP administration. This therapeutic protocol began in the first decade of the 21st century, based on the results of a randomized trial which compared R-CHOP with a CHOP regimen for elderly patients and showed an approximately 20% survival advantage in the R-CHOP arm. Recent developments of new drugs such as monoclonal antibody and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma, Large B-Cell, Diffuse

Share to Mutation

Share to Myeloid Differentiation Factor 88

Share to Signal Transduction

Share to Treatment Outcome

Source

Identifiers

PMID: 27795509
DOI: 10.11406/rinketsu.57.2013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diffuse large B-cell lymphoma: current standard treatment and future perspectives.PMID 27795509Read ↗

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.Semantic proximity Read ↗

Molecular pathogenesis and treatment strategy in diffuse large B-cell lymphoma.Semantic proximity Read ↗

[Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity].Semantic proximity Read ↗

Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review).Semantic proximity Read ↗

Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment.Semantic proximity Read ↗

Real-world Outcomes of Diffuse Large B-cell Lymphoma Treated with frontline R-CHOP(-like) regimens in an Asian Multi-ethnic PopulationSemantic proximity Read ↗

Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification.Semantic proximity Read ↗

Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approachSemantic proximity Read ↗

Lymphoma: turning biology into cures.Semantic proximity Read ↗

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity Read ↗

Novel therapeutic targets in diffuse large B-cell lymphomaSemantic proximity Read ↗

Diffuse large B cell lymphoma: molecular targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.